Pharmacotherapeutic group: macrolide antibiotic

Release form and packaging: 14 tabs in packaging.

Dosage form:
Pink film-coated tablets are capsular, biconvex. Two layers are visible on the cross section, the inner layer is white or almost white.

Composition of the active substance:
clarithromycin (in terms of active substance) 500 mg;

Semi-synthetic macrolide antibiotic with a wide spectrum of action. It disrupts the synthesis of protein of microorganisms (binds to the 50S subunit of the membrane of the ribosome of the microbial cell). It acts on extra - and intracellularly located pathogens. The activity of clarithromycin against most of the following microorganisms has been proven in vitro and in clinical practice, aerobic gram-positive microorganisms: Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes; aerobic gram-negative microorganisms: Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Legionella pneumophila; other microorganisms: Mycoplasma pneumoniae, Chlamydia pneumoniae; mycobacteria: Mycobacterium avium complex (MAC) - a complex including: Mycobacterium avium and Mycobacterium intracellulare; Helicobacter pylori. Beta-lactamases do not affect the activity of clarithromycin. In vitro clarithromycin activity - aerobic gram-positive microorganisms: Listeria monocytogenes, Streptococcus agalactiae, Streptococci of groups C, F, G, Streptococci of the viridans group; aerobic gram-negative microorganisms: Neisseria gonorrhoeae, Bordetella pertussis, Pasteurella multocida; anaerobic gram-positive microorganisms: Clostridium perfringens, Peptococcus niger, Propionibacterium acnes; anaerobic gram-negative microorganisms: Bacteroides melaninogenicus; spirochetes: Borrelia burgdorferi, Treponema pallidum; mycobacteria: Mycobacterium leprae, Mycobacterium chelonae, campylobacter: Campylobacter jejuni.
The microbiologically active metabolite of clarithromycin, 14-hydroxyclarithromycin, is twice as active as the parent compound against Haemophilus influenzae. Clarithromycin and its metabolite in combination can have both additive and synergistic effects on Haemophilus influenzae in vitro and in vivo, depending on the strain of the bacterium. Most strains of staphylococci resistant to methicillin and oxacillin are resistant to clarithromycin. Perhaps the development of cross-resistance to clarithromycin and other antibiotics of the macrolide group, as well as lincomycin and clindamycin.